Tune in as Duy Nguyen, PhD reflects on the final session of the #CancerEngineeringSummit.

Join Michael Dunne, PhD (@MRDunne) as he reflects on the session that he moderated, “Convergence at the Crossroads: More than a Delivery Challenge,” exploring how collaboration across disciplines is driving more effective solutions. #CancerEngineeringSummit

Live from the #CancerEngineeringSummit: Roger Li, MD (@UrogerliMD) explores gaps and opportunities in the treatment of bladder cancer. Conclusions and future outlook: •Critical unmet need for treating bladder cancer unresponsive to SOC. •Rational development of intravesical therapy can enhance therapeutic potential, promote understanding of the MOA while minimizing treatment toxicity. •Critical need for real-time measurement of drug penetration and treatment efficacy. •Need to solve the engineering problem of enhancing drug penetration.

At the #CancerEngineeringSummit, M.G. Finn (@GeorgiaTech) reflects on the session he moderated, “Science Applied to Life: 3M – Mechanics, Materials and Metabolism,” highlighting how interdisciplinary science is shaping the future of cancer engineering.

At the #CancerEngineeringSummit, Marcelo Bonini, PhD (@Marcelobonini20) shares insights on histone oxidation as a new mechanism of metabolic control over gene expression. Key takeaways: •Biosensors provide the unique opportunity to incorporate time as a dimension to biological assessments as tumors respond to selective pressures. •Chemogenic systems allow to dissect the biological functions of specific metabolites. •Development of organelle directed pharmaceuticals provides a unique opportunity to bioengineer more effective therapeutics.

Happening now: Kayvan Keshari, PhD (@KeshariLab @MSKCancerCenter) shares how metabolic engineering can power next-generation cell-based therapies, translating insights from in vivo cancer metabolism into more precise, effective treatment strategies. #CancerEngineeringSummit

Live from the #CancerEngineeringSummit: Liang Hao, PhD (@LiangHao_L2) discusses engineering precision diagnostics via multimodal activity profiling. She explores how we can translate a local tumor signature into a system readout.

Day 2 of the 2026 #CancerEngineeringSummit continues with impactful discussions and data-driven insights from leading cancer researchers. From emerging technologies to collaborative best practices, the focus remains clear: accelerating innovation in cancer engineering.

Today Andrew von Eschenbach, MD and @PeterForsyth27 presented impactful work at the #CancerEngineeringSummit!

Proud to recognize advances in cancer engineering at tonight’s #CancerEngineeringSummit reception! Thank you to our Day 1 presenters and attendees. We look forward to more discussion and collaboration tomorrow.

A pleasure to discuss our research and Cancer Engineering PhD Program at @MSKCancerCenter co-directed with Kayvan Keshari. Thank you @ProfGregSawyer for having us at the #CancerEngineeringSummit!

Greg Sawyer, PhD, (@ProfGregSawyer) closes Day 1 of the #CancerEngineeringSummit by highlighting exciting presentations on materials science, immunology and nanoparticles. We’re looking forward to more exciting sessions tomorrow!

During the #CancerEngineeringSummit poster session, Yuxi Zhou presents a novel 3D ex vivo ovarian cancer model that maintains patient tumor complexity and allows real-time drug testing in platinum-sensitive and resistant disease. This platform may improve therapeutic selection and advance personalized treatment approaches.

During the #CancerEngineeringSummit, Ashley Lui, PhD, shares research identifying TAp63-regulated oncogenic lncRNAs (TROLL-2/-3) as tumor-specific activators of the AKT pathway in high-grade serous ovarian cancer. Antisense oligonucleotide therapy reduced tumor proliferation in preclinical models, supporting a targeted, more precise therapeutic strategy.

From #CancerEngineeringSummit: Rana Falahat, PhD (@RanaFalahat), presents on bioengineering injectable, chitosan-based hydrogels to create tertiary lymphoid-like structures that support immune cell proliferation and enhance antitumor immunity.

During #CancerEngineeringSummit: Peter Forsyth, MD (@PeterForsyth27), shares his enthusiasm for collaborating with colleagues at Moffitt and the multidisciplinary nature of cancer engineering, and outlines current and emerging treatments for leptomeningeal disease, as well as excitement about the potential for cancer engineering to help find a cure.

Live from #CancerEngineeringSummit Blaise Kimmel, PhD (@BlaiseKimmel), presents research on logic-gated immunotherapies that integrate medicinal chemistry and T-cell immunology, bringing proteins and drugs together to expand biological control and advance the development of novel therapies.

Excited to attend the 2026 #CancerEngineeringSummit hosted by @MoffittNews bringing together cancer researchers from around the world to share innovative research that is accelerating progress in cancer engineering. Together, we are Engineering Cancer’s End.

Happening now at #CancerEngineeringSummit Steve Granick, PhD, of @UMassAmherst, shares research showing that epithelial skin cells generate electrical spikes similar to neurons, particularly after injury. Understanding these bioelectric signals could inform next-generation medical devices, underscoring the need for translational science to move this discovery into clinical therapies.

Live from #CancerEngineeringSummit: Andrew von Eschenbach, MD (@samhealth) shares how deeper understanding of cancer at the genetic, molecular and cellular level is opening new ways to intervene across the disease process—from detection to prevention.